Foundayo (orforglipron)
Foundayo has been approved as an adjunct to a healthy diet and physical activity to reduce excess body weight and maintain weight reduction and treat type 2 diabetes in adults who meet the relevant clinical criteria. Foundayo contains the active ingredient orforglipron.
Foundayo is approved in addition to a healthy diet and regular physical activity for weight management and the treatment of type 2 diabetes in eligible adults.
Foundayo is available as tablets and capsules.
Weight management
Foundayo can be prescribed to help adults lose weight and maintain weight loss, in addition to a healthy diet and regular physical activity, when they have:
- a body mass index (BMI) equal to or greater than 30 kg/m2 (obesity)
- a BMI equal to or greater than 27 kg/m2 to 30 kg/m2 (overweight) and at least one weight-related health condition, such as high blood pressure, dyslipidaemia (abnormal blood fats), prediabetes, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease.
Type 2 diabetes
Foundayo can be prescribed to treat adults with insufficiently controlled type 2 diabetes, in addition to a healthy diet and regular physical activity:
- as monotherapy (on its own) when metformin (a common first treatment for type 2 diabetes) is not appropriate due to intolerance or contraindications, or
- in addition to other medicines used to treat type 2 diabetes.
Overweight and obesity are long-term health conditions that can increase the risk of illness and reduced life expectancy.
Type 2 diabetes is a condition where blood glucose (sugar) levels are higher than normal. It occurs when the body does not respond properly to insulin and the pancreas does not produce enough insulin to control blood sugar (glucose) levels.
Foundayo belongs to a group of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists.
Foundayo contains the active ingredient orforglipron. Orforglipron is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. Naturally occurring GLP-1 helps control appetite and blood sugar levels.
Orforglipron attaches to and activates GLP-1 receptors in the brain and pancreas that are involved in regulating appetite and blood sugar levels.
Orforglipron can:
- reduce body weight and body fat by helping people feel less hungry and eat less (these effects may improve insulin sensitivity and lipid profiles)
- help the pancreas release insulin when needed and improve the body’s response to insulin, supporting better blood sugar control
- slow the movement of food from the stomach to the intestines, particularly when treatment is first started, which may help people feel full for longer after eating.
The effectiveness and safety of Foundayo for weight management, in combination with a healthy diet and physical activity, were assessed in 2 main clinical trials called the ATTAIN-1 and ATTAIN-2 studies.
ATTAIN-1 study: Weight management in adults without type 2 diabetes
- ATTAIN-1 assessed the effectiveness and safety of Foundayo compared with a placebo (treatment with no active ingredients) over 72 weeks.
- The study included 3,127 adults with obesity, or overweight and at least one weight-related health condition, who did not have type 2 diabetes.
ATTAIN-2 study: Weight management in adults with type 2 diabetes
- ATTAIN-2 assessed the effectiveness and safety of Foundayo compared with a placebo over 72 weeks.
- The study included 1,613 adults with obesity, or overweight and at least one weight-related health condition, who also had type 2 diabetes.
The effectiveness and safety of Foundayo for type 2 diabetes, in combination with a healthy diet and physical activity, were assessed in 4 main clinical studies (ACHIEVE-1, ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 studies). Three supporting studies (GZGE, GZPE and ATTAIN-2) also provided data on effectiveness in type 2 diabetes.
ACHIEVE-1 study – Monotherapy
- The ACHIEVE-1 study assessed the effectiveness and safety of Foundayo compared with the placebo over 40 weeks.
- The study included 559 adults with type 2 diabetes whose blood sugar levels were not adequately controlled with diet and physical activity alone.
ACHIEVE-2 study – Combination therapy with metformin compared to dapagliflozin
- The ACHIEVE-2 study compared Foundayo with dapagliflozin (an approved medicine for type 2 diabetes) over 40 weeks.
- The study included 962 adults with type 2 diabetes who were taking metformin (an established first line diabetes medicine).
ACHIEVE-3 study – Combination therapy with metformin compared to oral semaglutide
- The ACHIEVE-3 study compared Foundayo with oral semaglutide (another GLP-1 medicine used to treat type 2 diabetes) over 52 weeks.
- The study included 1,698 adults with type 2 diabetes who were taking metformin.
ACHIEVE-5 study – Combination therapy with insulin, with or without metformin and/or SGLT-2 inhibitor
- The ACHIEVE-5 study compared Foundayo with a placebo over 40 weeks.
- The study included 546 adults with type 2 diabetes whose blood sugar levels were inadequately controlled despite treatment with insulin glargine, with or without metformin and/or an SGLT-2 inhibitor.
Key findings from the weight management studies
- In the ATTAIN-1 study, all doses of Foundayo resulted in greater weight loss than the placebo after 72 weeks.
- The higher dose capsule, 36 mg once daily, reduced body weight by 9.1% more than the placebo, which exceeds the 5% weight loss threshold that the TGA consider clinically meaningful for weight management medicines. That is, the amount of weight lost was considered large enough to provide a meaningful health benefit.
- People taking Foundayo had a greater reduction in systolic (top number in a blood pressure reading) blood pressure, with an average decrease of about 4 to 5 mmHg, compared with about 1.5 mmHg for those taking the placebo.
- In addition, Orforglipron reduced levels of non-HDL cholesterol by about 6%, compared with about 2% to 3% for the placebo.
- The weight loss achieved by Foundayo was supported by reductions in waist circumference.
- In the ATTAIN-2 study, people taking Foundayo lost a greater percentage of their body weight over 72 weeks across all doses studied than those taking the placebo.
- Average weight loss was 5.12% of starting body weight with 6 mg capsule of Foundayo, 6.99% with 12 mg capsule and 9.61% with 36 mg capsule, compared with an average of 2.46% with the placebo.
- Less weight loss was observed with lower doses, and individual responses varied. These findings suggest that treatment expectations and dose selection may need to be tailored to each person.
Key findings from the type 2 diabetes studies
- In the ACHIEVE-1 study, HbA1c (a measure of blood sugar) levels after 40 weeks had decreased in patients treated with Foundayo by 1.24% with 3 mg capsule, 1.47% with 12 mg capsule, and 1.48% with 36 mg capsule, compared with 0.4% in patients taking the placebo.
- Decreases in blood sugar levels with Foundayo occurred within 4 weeks of starting treatment. The largest decreases occurred after 20 to 30 weeks, depending on the dose, and were maintained throughout the 40-week study.
- In the ACHIEVE-2 study, HbA1c decreased by 1.23% with Foundayo 3 mg capsule, 1.50% with 12 mg capsule, and 1.56% with 36 mg capsule at week 40, compared with 0.81% with dapagliflozin.
- In the ACHIEVE-3 study, HbA1c decreased by 1.71% with Foundayo 12 mg capsule and 1.91% with 36 mg capsule after 52 weeks. This compared with reductions of 1.23% with 7 mg oral semaglutide and 1.47% with 14 mg oral semaglutide.
- In the ACHIEVE-5 study, people taking Foundayo had greater reductions in HbA1c than those taking the placebo. After 40 weeks, HbA1c decreased by 1.58% with Foundayo 3 mg capsule, 1.88% with 12 mg capsule, and 1.82% with 36 mg capsule, compared with 0.79% with the placebo.
- Orforglipron was effective when used on its own and when used in combination with other diabetes medicines, including metformin and insulin.
The clinical trials used capsules instead of tablets. Studies showed the capsules and tablets work the same way in the body.
Safety and cardiovascular findings
- Clinical studies showed an average increase in heart rate during treatment and reductions in blood pressure.
- The clinical studies did not identify an increased risk of major cardiovascular events with orforglipron. Major adverse cardiovascular events (MACE), such as heart attack and stroke, were uncommon and occurred at similar rates in people taking Foundayo and those taking the placebo.
- The most commonly reported side effects with orforglipron were nausea, constipation, diarrhoea, vomiting, dyspepsia (indigestion), and were mostly mild to moderate.
- Overall, the safety findings for orforglipron were consistent with that expected for a GLP-1 receptor agonist.
The TGA decided that the application provided sufficient evidence supporting the quality, safety and effectiveness of Foundayo and the medicine can be registered in Australia.
More detailed information on why the TGA approved Foundayo will be published in the upcoming Australian Public Assessment Report (AusPAR).
For comprehensive information on potential side effects and risks, refer to the Consumer Medicine Information (CMI) leaflet or Product Information (PI) document.
This decision summary will not be updated to reflect any subsequent changes and may therefore not contain the most current information about the medicine. For the latest information, refer to the medicine’s CMI or PI.
The CMI leaflet offers guidance for consumers to support safe and effective use of the medicine. The CMI includes information on dose, how to use the medicine properly, potential side effects, safety precautions, storage instructions and more.
Australian CMIs can be accessed through the searchable TGA eBusiness Services or ARTG databases.
The PI document provides essential prescribing information for health professionals, including details on dosage recommendations, pregnancy category, contraindications, precautions and potential side effects.
Australian PIs can be accessed through the searchable TGA eBusiness Services or ARTG databases.
- FOUNDAYO orforglipron (as calcium) 0.8 mg film coated tablet blister pack (521939)
- FOUNDAYO orforglipron (as calcium) 12 mg hard capsule blister pack (521940)
- FOUNDAYO orforglipron (as calcium) 14.5 mg film coated tablet blister pack (521941)
- FOUNDAYO orforglipron (as calcium) 17.2 mg film coated tablet blister pack (521942)
- FOUNDAYO orforglipron (as calcium) 1 mg hard capsule blister pack (521943)
- FOUNDAYO orforglipron (as calcium) 2.5 mg film coated tablet blister pack (521944)
- FOUNDAYO orforglipron (as calcium) 24 mg hard capsule blister pack (521945)
- FOUNDAYO orforglipron (as calcium) 36 mg hard capsule blister pack (521946)
- FOUNDAYO orforglipron (as calcium) 3 mg hard capsule blister pack (521947)
- FOUNDAYO orforglipron (as calcium) 5.5 mg film coated tablet blister pack (521948)
- FOUNDAYO orforglipron (as calcium) 6 mg hard capsule blister pack (521949)
- FOUNDAYO orforglipron (as calcium) 9 mg film coated tablet blister pack (522875)
For health advice and information, including a symptom checker and service finder refer to the healthdirect website.
For free health advice or to speak to a registered nurse about any health concern call the 1800MEDICARE helpline.
For information on medicines subsidised by the Australian Government refer to the Pharmaceutical Benefits Scheme (PBS) website.
For data and reports on health and welfare topics in Australia refer to the Australian Institute of Health and Welfare website.
Patients should take either the Foundayo tablet or capsule. Both dosage forms should not be taken at the same time.